Diagnostic accuracy of the UBC® Rapid Test for bladder cancer: A meta-analysis

PEI LU1*, JIANCHUN CUI2*, KELIANG CHEN1*, QIANG LU1, JIEXIU ZHANG1, JUN TAO1, ZHUJIAN HAN1, WEI ZHANG1, RIJIN SONG1 and MIN GU1

1Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 2Department of Urology, The Jianhu County Traditional Chinese Medicine Hospital, Jianhu, Jiangsu 224700, P.R. China

Received December 23, 2017; Accepted May 30, 2018

DOI: 10.3892/ol.2018.9089

Abstract. Bladder cancer is one of the most common cancer types globally. The UBC® Rapid Test is a potential novel diagnostic method for bladder cancer, but studies into its accuracy have produced inconsistent results. Thus, the present meta-analysis was conducted in order to determine the overall accuracy of the UBC® Rapid Test in detecting bladder cancer. A comprehensive literature search was conducted using MEDLINE, Embase, Cochrane Library, Web of Science, Chinese WanFang and the China National Knowledge Infrastructure databases for relevant studies. Quality assessment of diagnostic accuracy studies was used to assess the quality of each included study. The diagnostic accuracy of the UBC® Rapid Test was evaluated by pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and the area under the curve (AUC). In addition, Deeks’ funnel plot was used to evaluate potential publication bias. Eight studies were included in the quantitative meta-analysis. The results were as follows: Sensitivity 0.59 [95% confidence interval (CI), 0.55-0.62], specificity 0.76 (95% CI, 0.72-0.80), PLR 2.55 (95% CI, 1.75-3.70), NLR 0.56 (95% CI, 0.46-0.67), DOR 4.88 (95% CI, 2.82-8.45) and AUC 0.70 (95% CI, 0.67-0.74). According to the present results, the UBC® rapid test is highly accurate in the diagnosis of bladder cancer, however, further studies with better-designed and larger samples are required in order to support the results of the present study.

Introduction

Bladder cancer was the ninth most common cancer type globally and the second most common urogenital malignancy in 2012 (1). More than 60% of bladder cancer cases occur in less well-developed countries, including China, and 75% of these cases occur in men (2). Furthermore, bladder cancer has a high recurrence rate (50%), and 15-40% of cases develop into a muscle-invasive form of the disease (3,4). Therefore, early diagnosis and consistent follow-up are necessary in order to improve patient quality of life.

Previously, the primary methods used to detect and follow up bladder cancer were cystoscopy and cytology (5). Cystoscopy is able to identify the majority of papillary and solid lesions and is therefore widely used. Cystoscopy combined with pathological biopsy is the gold standard for the diagnosis and follow-up of bladder cancer (6). However, it is not only an invasive procedure but also has limited accuracy in detecting certain lesions, particularly small areas of carcinoma in situ (7). While cytology has a specificity of >90%, its sensitivity is <44%, particularly in highly-differentiated tumor types (stages G1-G2) (8-10). Therefore, the invasive nature of cystoscopy and the low sensitivity of cytology limit the early diagnosis of bladder cancer in clinical practice. Consequently, a non-invasive, highly sensitive and specific alternative test is urgently required.

To identify a better method to diagnose bladder cancer, various urine-based tumor markers have been extensively investigated (7). These markers, including human complement factor H, cytokeratin 19 fragments and nuclear matrix protein 22, generally demonstrate a higher sensitivity but lower specificity compared with cytology (9,11,12). Biomarker diagnosis has not yet been recommended in the European Association of Urology guidelines (13). Recently, a novel non-invasive qualitative immunochromatographic test has been launched to identify the urinary bladder cancer antigen. The UBC® Rapid Test (Concile GmbH, Freiburg, Germany) is a point-of-care test, compliant with International Organization for Standardization 22870:2016, which may quantitatively measure fragments of cytokeratins 8 and 18 (14-16). These cytokeratins are located in the cytoskeleton of epithelial cells and tend to be overexpressed in urothelial tumor types including bladder cancer (17-19). Based on this, several
trials have been performed to investigate the efficacy of the UBC® Rapid Test in the detection and follow-up of bladder cancer (20-22). However, differences in the design and enrollment of these studies have resulted in inconsistent conclusions, so its diagnostic accuracy remains unclear.

In the present study, these previous studies were systematically reviewed to assess the diagnostic value of the UBC® Rapid Test in the detection and follow-up of bladder cancer.

**Materials and methods**

**Search strategy.** The following databases were comprehensively searched for studies published between January 1, 1990 and June 1, 2017: Pubmed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, China (WANFANG) and the China CNKI database. The search was performed using the following keywords in combination: (‘UBC’ OR ‘Cytokeratin 8’ OR ‘Cytokeratin 18’) AND (‘Bladder cancer’ OR ‘urinary bladder neoplasm’) as medical subject headings. Furthermore, the reference lists of all studies included in the meta-analysis were also reviewed for possible inclusion.

**Inclusion and exclusion criteria.** The inclusion criteria were as follows: i) Case-control or cohort design; ii) sufficient data for meta-analysis [true positive (TP), false positive (FP), false negative (FN) and true negative (TN)]; iii) if data or subsets of data were used in more than one article, the most recent article or the one with greater detail was selected; and iv) written in English or Chinese. The exclusion criteria were as follows: i) Reviews, case reports and letters to editors; ii) duplicate publications; iii) studies in languages other than English or Chinese; and iv) studies with insufficient data to construct a 2×2 table. All records were independently reviewed by Dr Pei Lu and Dr Rijin Song (Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China). Consensus was normally reached for each eligible study and any disagreements were resolved by consultation with a third reviewer (Dr Min Gu; Department of Urology, The First Affiliated Hospital of Nanjing Medical University).
Data extraction and quality assessment. Relevant data were extracted from the full text of the included studies and included: First author, publication year, ethnicity, sample size, mean age, sex, specific details of index test used, sensitivity and specificity, TP, FP, FN and TN for various grades of bladder tumor types.

The quality assessment of diagnostic accuracy studies (QUADAS-2) scale was used to evaluate the quality of the eligible studies (23). This contains four domains including patient selection, index test, reference standard and flow and timing. All domains were evaluated for the potential risk of bias and the first three were mainly concerned with applicability.

Statistical analysis. The accuracy indicators included pooled sensitivity, pooled specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and their 95% confidence intervals (CIs). These were calculated using the random effects model (24). The summary receiver operative curve (SROC), which reveals the association between sensitivity and the false positive rate, was used to evaluate the consistency of results between all studies in addition to the accuracy of the test (25). The area under the curve (AUC) was also calculated. Heterogeneity was measured using a Q test and the inconsistency index (I²) (26). P<0.05 or I²>50% was considered to indicate significant heterogeneity and therefore the random effects model was applied (27); otherwise the fixed-effect model was used. One of the most important causes of heterogeneity in diagnostic tests is the threshold effect. This occurs when the sensitivity and specificity are negatively correlated (or sensitivity is positively correlated with 1-specificity), resulting in a typical ‘shoulder arm’ of the ROC plane distribution. A Spearman correlation analysis was performed. Subsequently, meta-regression and subgroup analyses were conducted to explore potential sources of inter-study heterogeneity. Furthermore, Deeks’ funnel plots were used to detect any publication bias (28). All statistical analysis was conducted using Meta-Disc 1.4 software (Hospital Universitario Ramon y Cajal, Madrid, Spain) and STATA 12.0 software (StataCorp, LLC, College Station, TX, USA) (29,30).

Results

Study selection and characteristics. As presented in the flow chart (Fig. 1), a total of 14 potential relevant articles were identified initially, of which four were removed subsequent to reading the titles and abstracts in further detail. Following a full-text review, two studies were eliminated due to lack of sufficient data, leaving eight studies (14-16,22,31-34). The basic characteristics of the studies are summarized in Table I.

All eight studies were conducted in a European population, and the majority of the patients were male and >50 years old (Table I). Urinary sediment was used as a specimen, and cytology or cystoscopy was considered as the gold standard. The results of the quality assessment are presented in Fig. 2. The majority of articles included the majority of the QUADAS-2 domains, indicating that the overall quality of the included studies was moderate to high.
Threshold effect. The ROC curve of sensitivity against the specificity of each study (Fig. 3) revealed a non-typical shoulder arm appearance, indicating that there was no threshold effect. In addition, the calculated Spearman correlation coefficient value was 0.44 (P=0.27), also indicating no threshold effect.

Diagnostic accuracy. Overall, the sensitivity of the pooled data was 0.59 (95% CI=0.55-0.62) and the specificity was 0.76 (95% CI=0.72-0.80) (Fig. 4). The pooled PLR was 2.55 (95% CI=1.75-3.70), the NLR was 0.56 (95% CI=0.46-0.67) and the DOR was 4.88 (95% CI=2.82-8.45) (Figs. 5 and 6). The SROC curve for the eight studies is presented in Fig. 7. The overall AUC of the UBC® Rapid Test was 0.70 (95% CI=0.85-0.91). Significant heterogeneity was identified for pooled sensitivity (I²=78.8%, P<0.001; Fig. 4) and specificity (I²=82.1%, P<0.001; Fig. 4) so the random effects model was applied for further analysis.

Meta-regression and subgroup analysis. Heterogeneity was identified in the estimates of sensitivity, specificity, PLR,
NLR and DOR. Therefore, meta-regression was used to explore the source of heterogeneity on the basis of study design, double blinding and sample size. However, none of the above covariates were heterogeneous (all P>0.05; Table II). Although subgroup analysis, including design, blind and sample size, were performed, there was no difference in the diagnostic efficacy of this test, indicating none of the parameters were identified to be a source of heterogeneity (Table III).

Publication bias. Deeks’ funnel plot demonstrated no significant publication bias (P=0.70; Fig. 8).

Discussion

To date, cystoscopy has been considered the gold standard for detecting bladder cancer and for following up patients who have undergone tumor resection (35). However, it is an invasive and expensive tool. Another test widely used in clinical practice is urine cytology; however, its low sensitivity limits its use (36). Therefore, it is necessary to identify a viable, reliable and minimally-invasive method to detect new or recurrent bladder cancer.

The UBC® Rapid Test is a quantitative method to determine the levels of urinary fragments of cytokeratin 8 and 18, and has recently been developed as a tumor marker to detect bladder cancer (37). In the present analysis, the pooled AUC of the UBC® Rapid test indicated that it was a better diagnostic tool compared with cystoscopy and cytology. The DOR value, the ratio of correct to false diagnosis, is a comprehensive indicator of the diagnostic efficiency index (38). The pooled DOR in the present study suggested that the UBC® Rapid Test is reliable compared with the overall accuracy of bladder cancer diagnosis. The likelihood ratio, including PLR and NLR, is also a strong performance indicator for diagnostic experiments (39). Generally considered, a PLR>10 indicates the presence of disease, and a NLR<0.1 may rule out the possibility of disease. However, the present study revealed that the pooled PLR and NLR for the UBC® Rapid Test were 2.55 and 0.56, respectively. This suggests that the probability of the test providing a positive result in patients with bladder cancer was 2.55 times higher compared with patients without bladder cancer; and the probability of negative results was 0.56 times higher compared with in non-patients. Therefore, the performance of the UBC® Rapid Test in terms of pooled PLR and NLR did not meet
clinical practice requirements and should be further modified prior to clinical use.

Exploring heterogeneity is crucial to understanding the factors that affect accurate estimates in addition to the appropriateness of combining the accuracy of different studies (40). Substantial heterogeneity was identified in the present meta-analysis in terms of the pooled sensitivity, specificity, PLR, NLR and DOR. The threshold effect remains an important cause of heterogeneity in diagnostic trials (41). In the present meta-analysis, a significant threshold effect was not observed. To further explore the source of heterogeneity, a meta-regression analysis was used based on design, blinding...
and sample size. The results suggested that none of these parameters were the cause, indicating that other variables contributed to the heterogeneity across the studies; these may have been publication and choice bias.

Table II. Results of the multivariable meta-regression model for the characteristics with backward regression analysis.

| Variables | Coefficient | Standard error | P-value | RDOR | 95% confidence interval |
|-----------|-------------|----------------|---------|------|------------------------|
| Cte.      | 1.179       | 0.7577         | 0.2174  | -    | -                      |
| S         | -0.404      | 0.3753         | 0.3603  | -    | -                      |
| Design    | 0.798       | 0.7540         | 0.3673  | 2.22 | (0.20-24.49)           |
| Blinding  | -0.750      | 0.6327         | 0.3210  | 0.47 | (0.06-3.54)            |
| Sample size | 0.693     | 0.6791         | 0.3829  | 2.00 | (0.23-17.35)           |

Cte., constant coefficient; S, statistic S; RDOR, relative diagnostic odds ratio. Inverse variance weights; variables were retained in the regression model if P<0.05.

Table III. Summary results of diagnostic accuracy of UBC test for bladder cancer.

| Subgroup | No. of studies | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC |
|----------|----------------|----------------------|----------------------|--------------|--------------|--------------|-----|
| Design   |                |                      |                      |              |              |              |     |
| Retrospective | 2       | 0.56 (0.48, 0.65) | 0.88 (0.82, 0.93) | 4.08 (1.47, 11.33) | 0.49 (0.25, 0.94) | 8.45 (1.70, 42.05) | -   |
| Prospective | 6       | 0.59 (0.55, 0.63) | 0.71 (0.67, 0.76) | 2.0 (1.52, 2.64) | 0.58 (0.47, 0.70) | 3.81 (2.37, 6.12) | 0.6945 |
| Sample size |    |                      |                      |              |              |              |     |
| >150     | 3       | 0.68 (0.62, 0.74) | 0.75 (0.70, 0.79) | 2.78 (1.41, 4.03) | 0.47 (0.37, 0.59) | 6.11 (2.46, 15.16) | 0.7271 |
| ≤150     | 5       | 0.52 (0.47, 0.57) | 0.79 (0.72, 0.85) | 2.39 (1.49, 5.17) | 0.62 (0.50, 0.76) | 4.09 (1.97, 8.49) | 0.6392 |
| Blinding |                |                      |                      |              |              |              |     |
| Yes      | 5       | 0.61 (0.56, 0.67) | 0.72 (0.64, 0.79) | 2.39 (1.44, 3.96) | 0.59 (0.43, 0.79) | 4.18 (1.87, 9.31) | 0.7058 |
| No       | 3       | 0.56 (0.48, 0.65) | 0.88 (0.82, 0.93) | 3.47 (1.26, 9.58) | 0.51 (0.44, 0.59) | 6.30 (2.82, 14.06) | 0.7369 |
| Total    | 8       | 0.59 (0.55, 0.62) | 0.76 (0.72, 0.80) | 2.55 (1.75, 3.70) | 0.56 (0.46, 0.67) | 4.88 (2.82, 8.45) | 0.7046 |

CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve.

There are several limitations to the study. First, despite the extensive literature search, the number of studies and sample sizes included were small. Secondly, several papers published in different languages were excluded from the review, which may result in potential heterogeneity. Thirdly, all the trials included in this meta-analysis were retrospective, which may limit the conclusions due to the bias of choice.
In general, the present study suggests that the UBC® Rapid Test may be beneficial for the diagnosis of bladder cancer, since this non-invasive approach has a good overall diagnostic performance. However, further prospective, large-scale and multicenter assessments of clinical studies are required to fully assess the diagnostic role of the UBC® Rapid Test in patients with bladder cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81570676), the Science and Education Health Project of Jiangsu Province for Important Talent (grant no. RC2011055), the ‘333 High Level Talents Project’ in Jiangsu Province, China [grant nos. BRA2015469 and BRA2016514 (2015)], the Standardized Diagnosis and Treatment Research Program of Key Diseases in Jiangsu Province, China [grant no. BE2016791], the Open Program Project of Health Department of Jiangsu Province, China (grant no. JSY-2-2016-099), the Jiangsu Province Six Talents Peak from Department of Human Resources, Social Security Office of Jiangsu Province, China (grant no. 2010WSN-56), the General Program of Health Department of Jiangsu Province, China (grant no. H2009907) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (grant no. JX10231801).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

PL carried out the study design and preparation of the manuscript. JC carried out the study design and statistical analysis. KC performed the statistical analysis and preparation of the manuscript. QL performed the statistical analysis. JZ performed the statistical analysis and data collection. MG provided funding and study design.

Ethical approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, et al.: Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124: 2115-2124, 2018.
2. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 71: 96-108, 2017.
3. Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenzie JK, Montironi R, Paner GP, et al.: Update for the practicing pathologist: The international consultation on urologic disease-European association of urology consultation on bladder cancer. Mod Pathol 28: 612-630, 2015.
4. Kang M, Jeong CW, Kwak C, Kim HH and Ku JH: Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget 8: 12891-12901, 2017.
5. Liang B, He X, Shang D, Tian Y and Liu Z: The link between FOXJ1 expression level in bladder carcinoma and tumor recurrence. Oncol Lett 15: 1483-1486, 2018.
6. Soria P, Gurioli A, Peraldo F, Oderma M, Giona S, Ambrosini E, Frea B and Gottore F: Innovations in the endoscopic management of bladder cancer: Is the era of white light cystoscopy over. Urologia 80: 1-8, 2013.
7. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, et al.: Molecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensus. Urol Int 94: 1-24, 2015.
8. Mouw G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J and Vale L: Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14: 1-331, iii-iv, 2010.
9. Lotan Y and Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61: 109-118, 2003.
10. Schwalb DM, Herr HW and Fair WR: The management of clinically unconfirmed positive urinary cytology. J Urol 150: 1751-1756, 1993.
11. Kamat AM, Hahn NM, Efthathiou JA, Lerner SP, Malmström PU, Choi W, Lotan Y and Kassouf W: Bladder cancer 388: 2796-2810, 2016.
12. Dawam D: Biomarkers of bladder cancer in urine: Evaluation of diagnostic and prognostic significance of current and potential markers. Bladder Cancer—from Basic Science to Robotic Surgery. Abraham J and Andi Canda (ed). InTech Europe, Rijeka, 2012. https://www.intechopen.com/books/bladder-cancer-from-basic-science-to-robotic-surgery-biomarkers-of-bladder-cancer-in-urine-evaluation-of-diagnostic-and-prognostic-significance-of-current. Accessed February 1, 2012.
13. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Debret T, Ribal MJ, Van der Heijden AG and Sherif A; European Association of Urology: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 65: 778-792, 2014.
14. Ritter R, Hennenlotter J, Kühs U, Hofmann U, Außerkammler S, Blutbacher P, Deja A, Hohneder A, Gerber V, Gakis G, et al.: Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol 32: 337-344, 2014.
15. Ecke TH, Arndt C, Stephan C, Hallmann S, Lux O, Otto T, Ruttiloff J and Gerullis H: Preliminary results of a multicentre study of the UBC rapid test for detection of urinary bladder cancer. Anticancer Res 35: 2651-2655, 2015.
16. Nygard K, Jihansha V, Haugen M, Szilvéryi G, Einarsrud R, Malmström PU and Sherif A: Evaluation of the diagnostic accuracy of UBC® Rapid in bladder cancer: A Swedish multicentre study. Scand J Urol 51: 293-300, 2017.
17. Barak V, Goike H, Panaretakis W and Einarsrud R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540, 2004.
18. Sumi S, Arai K, Kitahara S and Yoshida KI: Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: Comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 296: 111-120, 2000.
19. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H and Dimopoulos C: Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 166: 470-475, 2001.

20. Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T and Johnen G: Evaluation of a new survivin ELISA and UBC® Rapid for the detection of bladder cancer in urine. Int J Mol Sci 19: pii: E226, 2018.

21. Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W and Heidegger I: Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study. Int J Med Sci 14: 811-819, 2017.

22. Ecke TH, Weiß S, Stephan C, Hallmann S, Barski D, Otto T and Gerullis H: UBC® Rapid test for detection of carcinoma in situ for bladder cancer. Tumour Biol 39: 1010428317701624, 2017.

23. Schueler S, Schuetz GM and Dewey M: The revised QUADAS-2 tool. Ann Intern Med 156: 323-324, 2012.

24. Rosenblat MA, Perrotta AS and Vicenzino B: Polarized vs. threshold training intensity distribution on endurance sport performance: A systematic review and meta-analysis of randomized controlled trials. J Strength Cond Res: May 30, 2018 (Epub ahead of print).

25. Hajian-Tilaki K: Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med 4: 627-635, 2013.

26. Bae JM: An overview of systematic reviews of diagnostic tests accuracy. Epidemiol Health 36: e2014016, 2014.

27. Gopalakrishna G, Langendam MW, Scholten RJ, Bossuyt PM and Leeflang MM: Defining the clinical pathway in cochrane diagnostic test accuracy reviews. BMC Med Res Methodol 16: 153, 2016.

28. van Enst WA, Ochodo E, Scholten RJ, Hootf L and Leeflang MM: Investigation of publication bias in meta-analyses of diagnostic test accuracy: A meta-epidemiological study. BMC Med Res Methodol 14: 70, 2014.

29. Zamora J, Abraira V, Muriel A, Khan K and Coomarasamy A: Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol 6: 31, 2006.

30. Deeks JJ, Macaskill P and Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893, 2005.

31. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M and Pycha A: Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 56: 228-231, 2000.

32. Babjuk M, Kostírová M, Mudra K, Pecher S, Smolová H, Pecen L, Ibrahim Z, Dvoráček J, Jarolím L, Novák J and Zima T: Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 41: 34-39, 2002.

33. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, Friedrich MG, Ekici S, Huland H and Lokeswar V: A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 172: 1123-1136, 2004.

34. Hakenberg OW, Fuessel S, Richter K, Froehnner M, Oehlenschlaeger S, Rathert P, Meye A and Wirth MP: Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64: 1121-1126, 2004.

35. Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martinez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P, et al: UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics 9: 8, 2017.

36. Burger M, Grossman HB, Droller M, Schmidbauer J, Herrmann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, et al: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 64: 846-854, 2013.

37. Xylinas E, Kloth LA, Rieken M, Karakiewicz PI, Lotan Y and Shariat SF: Urine markers for detection and surveillance of bladder cancer. Urol Oncol 32: 222-229, 2014.

38. Glas AS, Lijmer JG, Prins MH, Bosselijt GJ and Bossuyt PM: The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 56: 1129-1135, 2003.

39. Sedighi I: Interpretation of diagnostic tests: Likelihood ratio vs. Predictive value. Iran J Pediatr 23: 717, 2013.

40. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339: b2700, 2009.

41. Rubia K, Alegría AA, Cubillo AI, Smith AB, Brammer MJ and Radua J: Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Biol Psychiatry 76: 616-628, 2014.